Podcasts about Cervical cancer

Many cervical cancers are linked to the HPV virus. However, thanks to screening advancements, early detection of the cancer resulting in effective treatment is possible. Toni Kilts, DO, discusses screening guidelines and cervical cancer prevention.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Cancer Doesn't Wait, So Why Should Diagnosis? - Nassra Nesu, Cervical Cancer Survivor | #DriveInn 

Women make up half the population in Canada yet there are still major gaps in women's health research. Experts say investments addressing this gap could add years to life and boost the global economy. The Agenda invites Carmen Wyton, Chair and Founder of Women's Health Coalition of Canada; Dr. Amanda Black, Professor of, Obstetrics and Gynecology at The University of Ottawa; and Christine Faubert, Vice President of Health Equity & Mission Impact, at the Heart and Stroke Foundation of Canada to discuss.See omnystudio.com/listener for privacy information.

At-home cervical cancer screening device gains clearance; the FDA indicates it wants to remove pediatric fluoride products from the market; the chikungunya vaccine is put on-pause for some individuals; a subcutaneous autoinjector is approved to treat migraines; and the FDA will review a gene therapy for Hunter syndrome.

AP correspondent Ed Donahue reports on a new at-home medical test kit.

Dr. Shannon McLaughlin-David discusses the complexities of cervical cancer, HPV, and the role of gynecologic oncology. The dialogue explores the emotional and clinical challenges faced by both patients and clinicians, emphasizing the importance of effective communication and empathy in patient care. The discussion also highlights the various types of gynecologic cancers, surgical interventions, and the difficult decisions patients must make regarding their treatment options. This conversation delves into the complexities of patient autonomy, the emotional challenges faced by oncologists, and the systemic incentives within healthcare that can impact patient care. The discussion also covers the evolution of cervical cancer screening guidelines, the role of HPV in cervical cancer, and the importance of patient advocacy and education regarding vaccination.Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI research study here: https://www.google.com/url?q=https://pubmed.ncbi.nlm.nih.gov/33632649/&sa=D&source=editors&ust=1746483503903350&usg=AOvVaw0SNo_jk-rzoVp85P5E3s6F ‘Effect of 2 Interventions on Cervical Cancer Screening Guideline Adherence'Chapter Codes00:00 Introduction to Cervical Cancer and HPV02:49 The Journey to Gynecologic Oncology05:57 Understanding Gynecologic Cancers09:05 Surgical Interventions in Gynecologic Oncology11:59 The Complexity of Patient Decisions15:07 Patient-Clinician Communication Challenges17:45 The Role of Empathy in Oncology21:05 Navigating Hormonal Treatments and Patient Reactions27:30 Navigating Patient Autonomy and Medical Ethics29:47 The Emotional Toll of Oncology33:00 Understanding the Healthcare System's Incentives35:58 The Role of Patient Advocacy39:05 The Evolution of Cervical Cancer Screening Guidelines51:46 HPV and Its Impact on Cervical Cancer54:48 Current Screening Protocols and HPV VaccinationConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://www.youtube.com/@mantacares/videosSpotify: https://open.spotify.com/episode/0rSG16JUXGnRmOPfpJSplS?si=ayogPMUMT4eHJclXn6_5xA Apple: https://podcasts.apple.com/us/podcast/the-microbiomes-impact-on-colorectal-cancer/id1622669098?i=1000705538270 Tags & Keywords:cervical cancer, HPV, gynecologic oncology, patient communication, surgical interventions, women's health, cancer treatment, patient empathy, decision making, hormonal therapy, patient autonomy, medical ethics, oncology, healthcare system, patient advocacy, cervical cancer, HPV, screening guidelines, emotional toll, healthcare incentives#Storytelling #Identity #Representation #Authenticity #Podcast #Culture #CancerAwareness #MedicalPodcast #CancerSurvivor #Oncology #Healthcare #CancerSupport #PatientStories #CancerResearch #HealthPodcast #CancerCommunity #SurvivorStories #MentalHealth #Wellness #HealthcareInnovationDisclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

In this episode of the GOSH Podcast, host Carly returns to speak with Ashley Greer, a resilient cervical cancer survivor and passionate advocate. Diagnosed in late 2023, Ashley shares her powerful story of navigating treatment—including chemotherapy, radiation, and multiple surgeries—and how she found strength and purpose through it all. Now cancer-free, Ashley is on a mission to raise awareness about early detection and inspire others with her experience of life after cancer. Tune in for an honest, moving, and empowering conversation. Resources:Ashley's Instagram: @ashleys.pathCarly's Instagram: @ostomate_and_the_cityFor more information on the Gynecologic Cancer Initiative, please visit https://gynecancerinitiative.ca/ or email us at info@gynecancerinitiative.ca Where to learn more about us: Twitter – @GCI_Cluster Instagram – @gynecancerinitiative Facebook – facebook.com/gynecancerinitiativeTikTok – @gci_gosh

This week Bobbi Conner talks with MUSC's Dr. Trisha Amboree about research showing higher rates of cervical cancer in women living in rural counties in the U.S.

Cervical cancer remains a significant public health concern, but innovative approaches and community-based research are transforming prevention efforts, particularly immigrant communities. With over 600,000 new cases diagnosed annually, early detection and prevention strategies are crucial. However, accessibility and awareness gaps persist in immigrant communities due to language barriers, cultural stigma, and limited healthcare access. Community-based research plays a pivotal role in bridging these gaps. In engaging local populations through culturally sensitive outreach ensures that prevention strategies are accepted and effective. University of Miami Chief Health Equity Officer, Dr. Erin Kobetz, discusses how integrating cutting-edge technology with community engagement, moves us closer to reducing cervical cancer incidence and mortality rates, fostering a healthier future for immigrant populations. Series: "Exploring Ethics" [Humanities] [Science] [Show ID: 40464]

Cervical cancer remains a significant public health concern, but innovative approaches and community-based research are transforming prevention efforts, particularly immigrant communities. With over 600,000 new cases diagnosed annually, early detection and prevention strategies are crucial. However, accessibility and awareness gaps persist in immigrant communities due to language barriers, cultural stigma, and limited healthcare access. Community-based research plays a pivotal role in bridging these gaps. In engaging local populations through culturally sensitive outreach ensures that prevention strategies are accepted and effective. University of Miami Chief Health Equity Officer, Dr. Erin Kobetz, discusses how integrating cutting-edge technology with community engagement, moves us closer to reducing cervical cancer incidence and mortality rates, fostering a healthier future for immigrant populations. Series: "Exploring Ethics" [Humanities] [Science] [Show ID: 40464]

Cervical cancer remains a significant public health concern, but innovative approaches and community-based research are transforming prevention efforts, particularly immigrant communities. With over 600,000 new cases diagnosed annually, early detection and prevention strategies are crucial. However, accessibility and awareness gaps persist in immigrant communities due to language barriers, cultural stigma, and limited healthcare access. Community-based research plays a pivotal role in bridging these gaps. In engaging local populations through culturally sensitive outreach ensures that prevention strategies are accepted and effective. University of Miami Chief Health Equity Officer, Dr. Erin Kobetz, discusses how integrating cutting-edge technology with community engagement, moves us closer to reducing cervical cancer incidence and mortality rates, fostering a healthier future for immigrant populations. Series: "Exploring Ethics" [Humanities] [Science] [Show ID: 40464]

Cervical cancer remains a significant public health concern, but innovative approaches and community-based research are transforming prevention efforts, particularly immigrant communities. With over 600,000 new cases diagnosed annually, early detection and prevention strategies are crucial. However, accessibility and awareness gaps persist in immigrant communities due to language barriers, cultural stigma, and limited healthcare access. Community-based research plays a pivotal role in bridging these gaps. In engaging local populations through culturally sensitive outreach ensures that prevention strategies are accepted and effective. University of Miami Chief Health Equity Officer, Dr. Erin Kobetz, discusses how integrating cutting-edge technology with community engagement, moves us closer to reducing cervical cancer incidence and mortality rates, fostering a healthier future for immigrant populations. Series: "Exploring Ethics" [Humanities] [Science] [Show ID: 40464]

Cervical cancer remains a significant public health concern, but innovative approaches and community-based research are transforming prevention efforts, particularly immigrant communities. With over 600,000 new cases diagnosed annually, early detection and prevention strategies are crucial. However, accessibility and awareness gaps persist in immigrant communities due to language barriers, cultural stigma, and limited healthcare access. Community-based research plays a pivotal role in bridging these gaps. In engaging local populations through culturally sensitive outreach ensures that prevention strategies are accepted and effective. University of Miami Chief Health Equity Officer, Dr. Erin Kobetz, discusses how integrating cutting-edge technology with community engagement, moves us closer to reducing cervical cancer incidence and mortality rates, fostering a healthier future for immigrant populations. Series: "Exploring Ethics" [Humanities] [Science] [Show ID: 40464]

In this powerful episode of the Cervivor Podcast, host Joslyn Paguio sits down with cervical cancer survivors Lisa Lakey, Ann Marie Hartung, Gabrielle McCord, and Christy Chambers to share their journeys from diagnosis to survivorship. They discuss the challenges of treatment, cultural perspectives on cancer, and the barriers they faced in accessing healthcare. Through advocacy and storytelling, they highlight the importance of diversity, inclusion, and community support in the survivor experience. Tune in for an inspiring conversation on resilience, empowerment, and the fight for better healthcare for all.Did you connect with this episode? Share your thoughts with us on social media using #CervivorPodcast or by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠emailing us.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  For more Cervivor-related content, check out: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cervivor.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Follow Cervivor on all social media platforms. If you would like to be interviewed as a potential guest for an upcoming episode or would like to request a speaker or topic for a future podcast episode, email us at info@cervivor.org.

First, we talk to The Indian Express' Sweety Kumari about the violent protests that broke out in West Bengal's Murshidabad. Last week, protests against the Waqf Amendment Act in Murshidabad got violent, leading to three deaths. Sweety talks about what happened, the families of the deceased, and the current situation in the area.Next, we talk to The Indian Express' Anonna Dutt about a new blood test developed by the doctors at the All India Institute of Medical Sciences (AIIMS) that may help monitor the effectiveness of cervical cancer treatment. (16:22)And lastly, we talk about Omar Abdullah being hopeful that statehood will soon be restored for Jammu and Kashmir. (27:32)Hosted by Niharika Nanda and Ichha SharmaProduced and hosted by Niharika Nanda, Ichha Sharma and Shashank BhargavaEdited and mixed by Suresh Pawar

Story at-a-glance Gardasil's ability to prevent cervical cancer is being questioned, with experts citing a lack of long-term studies proving reduced cancer rates While Gardasil targets specific HPV strains, concerns exist that it allows for the emergence of other harmful strains, thus canceling the vaccine's intended benefits Reports of severe side effects, including heart complications and even deaths, raise serious safety concerns, warranting caution The vaccine's aggressive marketing, despite the proven effectiveness of regular pap smears, suggests Gardasil's benefits have been exaggerated while risks have been downplayed Lawsuits alleging that Merck concealed risks and overstated Gardasil's efficacy are underway, casting doubt on the company's transparency and raising trust issues regarding pharmaceutical marketing

In this episode I'm going to be covering 5 foods to include in your diet to help clear high risk HPV and prevent HPV-related cancers such as cervical and vaginal cancer. I know how confusing it can be to figure out what to eat and what not to eat. Once you realize that the food you feed your body each day can be your medicine and actually help prevent health issues, you start to understand the importance of choosing foods that will do the most good for you. I'm Dr. Doni Wilson, a naturopathic doctor, clinical nutritionist, and midwife. I've been practicing for over 25 years and specialize in women's health, particularly helping women with abnormal pap smears as well as humans with various different stress-related health issues. I want to emphasize that the food choices I'll be mentioning here will help your overall health. It's not that they only help with abnormal pap results or high risk HPV. When we choose these foods, they help our whole health. Most often, when women test positive for high risk HPV, they are also dealing with other health issues in their body—whether that's digestive issues, skin issues, weight issues, anxiety, depression, mental health issues, sleep issues, autoimmunity, hormone imbalances, or other health concerns. The foods I'll cover in this video will help with any and all of these health issues. Our priority is to choose foods to help support your immune system protect you from high risk HPV so you can clear it to negative and prevent it from coming back again. We're here to help! LINKS FROM THE EPISODE:   Join Dr. Doni's HPV Workshop: https://hpv.doctordoni.com/hpv/hpv-workshop   Sign up For Dr. Doni's Masterclasses: https://doctordoni.com/masterclasses/    Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx    Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI:   Quick links to social media, free guides and programs, and more: https://doctordoni.com/links     Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.  

This week's episode of Sistas, Let's Talk is a repeat of the show broadcast on 8th June 2023It's easier than ever to test for the virus that causes cervical cancer and more screening programs means fewer women will die from this preventable cancer.

A safe alternative to clinician-administered tests, the self-test for HPV can help prevent cervical cancer. Synopsis: Every first Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. HPV or the human papillomavirus is a common virus that is sexually transmitted, and while most HPV infections clear on their own, persistent infections with high-risk types can lead to cervical cancer. In March 2025, the Society for Colposcopy & Cervical Pathology of Singapore (SCCPS) published an updated set of national cervical cancer screening guidelines. The guidelines now recommend HPV self-sampling as an option to traditional cervical cancer screening methods. In Singapore, cervical cancer is currently the 11th most common cancer in women, with 309 new cases and 172 deaths in 2023, according to data from the Catalan Institute of Oncology (ICO) and the International Agency for Research on Cancer (IARC) Information Centre on HPV and Cancer. However, cervical cancer is one of the most preventable and treatable forms of cancer, as long as it is detected early and managed effectively, said the World Health Organisation (WHO). It aims to eliminate cervical cancer as a public health problem by 2030, with the following strategy: Vaccinate 90 per cent of girls with preventive HPV vaccines by age 15; Screen 70 per cent of women with a high-performance test like HPV DNA screening by age 35, and again by age 45; Treat 90 per cent of women who have precancerous cells in the cervix or cervical cancer. In this episode, senior health correspondent Joyce Teo speaks to Dr Felicia Chin, an obstetrician and gynaecological oncologist at Gynae Onco Partners about HPV DNA self-testing, what it entails, and who should screen for cervical cancer. Until late last year, Dr Chin was a senior consultant at KK Women’s and Children’s Hospital. She sits on the SCCPS committee. Highlights (click/tap above) 1:54 Explaining the various tests for cervical cancers 3:14 Guidelines for cervical cancer screening in Singapore 4:32 How does HPV self-sampling work? 5:23 Difference between a self-test and a pap smear 13:42 Cervical cancer symptoms Read Joyce Teo's stories: https://str.sg/JbxN Host: Joyce Teo (joyceteo@sph.com.sg) Produced and edited by: Amirul Karim & Eden Soh Executive producers: Ernest Luis and Lynda Hong Follow Health Check Podcast here and get notified for new episode drops: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Feedback to: podcast@sph.com.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 ST Podcasts website: http://str.sg/stpodcasts ST Podcasts YouTube: https://str.sg/4Vwsa --- Get The Straits Times app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX --- #healthcheckSee omnystudio.com/listener for privacy information.

A safe alternative to clinician-administered tests, the self-test for HPV can help prevent cervical cancer. Synopsis: Every first Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. HPV or the human papillomavirus is a common virus that is sexually transmitted, and while most HPV infections clear on their own, persistent infections with high-risk types can lead to cervical cancer. In March 2025, the Society for Colposcopy & Cervical Pathology of Singapore (SCCPS) published an updated set of national cervical cancer screening guidelines. The guidelines now recommend HPV self-sampling as an option to traditional cervical cancer screening methods. In Singapore, cervical cancer is currently the 11th most common cancer in women, with 309 new cases and 172 deaths in 2023, according to data from the Catalan Institute of Oncology (ICO) and the International Agency for Research on Cancer (IARC) Information Centre on HPV and Cancer. However, cervical cancer is one of the most preventable and treatable forms of cancer, as long as it is detected early and managed effectively, said the World Health Organisation (WHO). It aims to eliminate cervical cancer as a public health problem by 2030, with the following strategy: Vaccinate 90 per cent of girls with preventive HPV vaccines by age 15; Screen 70 per cent of women with a high-performance test like HPV DNA screening by age 35, and again by age 45; Treat 90 per cent of women who have precancerous cells in the cervix or cervical cancer. In this episode, senior health correspondent Joyce Teo speaks to Dr Felicia Chin, an obstetrician and gynaecological oncologist at Gynae Onco Partners about HPV DNA self-testing, what it entails, and who should screen for cervical cancer. Until late last year, Dr Chin was a senior consultant at KK Women’s and Children’s Hospital. She sits on the SCCPS committee. Highlights (click/tap above) 1:54 Explaining the various tests for cervical cancers 3:14 Guidelines for cervical cancer screening in Singapore 4:32 How does HPV self-sampling work? 5:23 Difference between a self-test and a pap smear 13:42 Cervical cancer symptoms Read Joyce Teo's stories: https://str.sg/JbxN Host: Joyce Teo (joyceteo@sph.com.sg) Produced and edited by: Amirul Karim & Eden Soh Executive producers: Ernest Luis and Lynda Hong Follow Health Check Podcast here and get notified for new episode drops: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Feedback to: podcast@sph.com.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 ST Podcasts website: http://str.sg/stpodcasts ST Podcasts YouTube: https://str.sg/4Vwsa --- Get The Straits Times app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX --- #healthcheckSee omnystudio.com/listener for privacy information.

Southern Remedy Healthy and Fit is hosted by Josie Bidwell, Professor of Preventive Medicine and Nurse Practitioner at UMMC. If you have a question for Josie, you can email fit@mpbonline.org. It this episode, Josie talks about upcoming See Test and Treat program at UMMC. The program screens for cervical cancer and a number of other things. Her guests are Dr. Varsha Manucha, a pathologist at UMMC and Jimmie Wells, the See Test and Treat program coordinator. Hosted on Acast. See acast.com/privacy for more information.

It is estimated that more than 14,000 women in the United States suffer from cervical cancer each year. Kentucky has a higher cervical cancer burden than most states, with an incidence rate of 9.6 cases per 100,000 women. Many of those cases were preventable, according to this week's guest, Charles S. Dietrich III, M.D., a gynecologic oncologist at the UK Markey Cancer Center.

Dr. Ebony Hoskins and Dr. Andreas Obermair discuss the surgical management of gynecologic cancers, including the role of minimally invasive surgery, approaches in fertility preservation, and the nuances of surgical debulking. TRANSCRIPT Dr. Ebony Hoskins: Hello and welcome to the ASCO Daily News Podcast, I'm Dr. Ebony Hoskins. I'm a gynecologic oncologist at MedStar Washington Hospital Center in Washington, DC, and your guest host of the ASCO Daily News Podcast. Today we'll be discussing the surgical management of gynecologic cancer, including the role of minimally invasive surgery (MIS), approaches in fertility preservation, and the nuances of surgical debulking, timing, and its impact on outcomes. I am delighted to welcome Dr. Andreas Obermair for today's discussion. Dr. Obermair is an internationally renowned gynecologic oncologist, a professor of gynecologic oncology at the University of Queensland, and the head of the Queensland Center for Gynecologic Cancer Research. Our full disclosures are available in the transcript of this episode. Dr. Obermair, it's great speaking with you today. Dr. Andreas Obermair: Thank you so much for inviting me to this podcast. Dr. Ebony Hoskins: I am very excited.  I looked at your paper and I thought, gosh, is everything surgical? This is everything that I deal with daily in terms of cancer in counseling patients. What prompted this review regarding GYN cancer management? Dr. Andreas Obermair: Yes, our article was published in the ASCO Educational Book; it is volume 44 in 2024. And this article covers some key aspects of targeted precision surgical management principles in endometrial cancer, cervical cancer, and ovarian cancer. While surgery is considered the cornerstone of gynecologic cancer treatment, sometimes research doesn't necessarily reflect that. And so I think ASCO asked us to; so it was not just me, there was a team of colleagues from different parts of the United States and Australia to reflect on surgical aspects of gynecologic cancer care and I feel super passionate about that because I do believe that surgery has a lot to offer. Surgical interventions need to be defined and overall, I see the research that I'm doing as part of my daily job to go towards precision surgery. And I think that is, well, that is something that I'm increasingly passionate for. Dr. Ebony Hoskins: Well, I think we should get into it. One thing that comes to mind is the innovation of minimally invasive surgery in endometrial cancer. I always reflect on when I started my fellowship, I guess it's been about 15 years ago, all of our endometrial cancer patients had a midline vertical incision, increased risk of abscess, infections and a long hospital stay. Do you mind commenting on how you see management of endometrial cancer today? Dr. Andreas Obermair: Thank you very much for giving the historical perspective because the generation of gynecologic oncologists today, they may not even know what we dealt with, what problems we had to solve. So like you, when I was a fellow in gynecologic oncology, we did midline or lower crosswise incisions, the length of stay was, five days, seven days, but we had patients in hospital because of complications for 28 days. We took them back to the operating theaters because those are patients with a BMI of 40 plus, 45, 50 and so forth. So we really needed to solve problems. And then I was exposed to a mentor who taught minimal invasive surgery. And in Australia he was one of the first ones who embarked on that. And I can remember, I was mesmerized by this operation, like not only how logical this procedure was, but also we did rounds afterwards. And I saw these women after surgery and I saw them sitting upright, lipstick on, having had a full meal at the end of the day. And I thought, wow, this is the most rewarding experience that I have to round these patients after surgery. And so I was thinking, how could I help to establish this operation as standard? Like a standard that other people would accept this is better. And so I thought we needed to do a trial on this. And then it took a long time. It took a long time to get the support for the [LACE - Laparoscopic Approach to Cancer of the Endometrium] trial. And in this context, I just also wanted to remind us all that there were concerns about minimal invasive surgery in endometrial cancer at the time. So for example, one of the concerns was when I submitted my grant funding applications, people said, “Well, even if we fund you, wouldn't be able to do this trial because there are actually no surgeons who actually do minimally invasive surgery.” And at the time, for example, in Australia, there were maybe five people, a handful of people who were able to do this operation, right? This was about 20 years ago. The other concern people had was they were saying, could minimally invasive surgery for endometrial cancer, could that cause port side metastasis because there were case reports. So there were a lot of things that we didn't know anyway. We did this trial and I'm super happy we did this trial. We started in 2005, and it took five years to enroll. At the same time, GOG LAP2 was ramping up and the LACE trial and GOG LAP2 then got published and provided the foundations for minimally invasive surgery in endometrial cancer. I'm super happy that we have randomized data about that because now when we go back and now when people have concerns about this, should we do minimally invasive surgery in P53 mutant tumors, I'm saying, well, we actually have data on that. We could go back, we could actually do more research on that if we wanted to, but our treatment recommendations are standing on solid feet. Dr. Ebony Hoskins: Well, my patients are thankful. I see patients all the time and they have high risk and morbidly obese, lots of medical issues and actually I send them home most the same day. And I think, you know, I'm very appreciative of that research, because we obviously practice evidence-based and it's certainly a game changer. Let's go along the lines of MIS and cervical cancer. And this is going back to the LACC [Laparoscopic Approach to Cervical Cancer] trial.  I remember, again, one of these early adopters of use of robotic surgery and laparoscopic surgery for radical hysterectomy and thought it was so cool. You know, we can see all the anatomy well and then have the data to show that we actually had a decreased survival. And I even see that most recent updated data just showing it still continued. Can you talk a little bit about why you think there is a difference? I know there's ongoing trials, but still interested in kind of why do you think there's a survival difference? Dr. Andreas Obermair:  So Ebony, I hope you don't mind me going back a step. So the LACC study was developed from the LACE trial. So we thought we wanted to reproduce the LACE data/LAP2 data. We wanted to reproduce that in cervix cancer. And people were saying, why do you do that? Like, why would that be different in any way? We recognize that minimally invasive radical hysterectomy is not a standard. We're not going to enroll patients in a randomized trial where we open and do a laparotomy on half the patients. So I think the lesson that really needs to be learned here is that any surgical intervention that we do, we should put on good evidence footing because otherwise we're really running the risk of jeopardizing patients' outcomes. So, that was number one and LACC started two years after LACE started. So LACC started in 2007, and I just wanted to acknowledge the LACC principal investigator, Dr. Pedro Ramirez, who at the time worked at MD Anderson. And we incidentally realized that we had a common interest. The findings came totally unexpected and came as an utter shock to both of us. We did not expect this. We expected to see very similar disease-free and overall survival data as we saw in the endometrial cancer cohort. Now LACC was not designed to check why there was a difference in disease-free survival. So this is very important to understand. We did not expect it. Like, so there was no point checking why that is the case. My personal idea, and I think it is fair enough if we share personal ideas, and this is not even a hypothesis I want to say, this is just a personal idea is that in endometrial cancer, we're dealing with a tumor where most of the time the cancer is surrounded by a myometrial shell. And most of the time the cancer would not get into outside contact with the peritoneal cavity. Whereas in cervix cancer, this is very different because in cervix cancer, we need to manipulate the cervix and the tumor is right at the outside there. So I personally don't use a uterine manipulator. I believe in the United States, uterine manipulators are used all the time. My experience is not in this area, so I can't comment on that. But I would think that the manipulation of the cervix and the contact of the cervix to the free peritoneal cavity could be one of the reasons. But again, this is simply a personal opinion. Dr. Ebony Hoskins: Well, I appreciate it. Dr. Andreas Obermair: Ebony at the end of the day, right, medicine is empirical science, and empirical science means that we just make observations, we make observations, we measure them, and we pass them on. And we made an observation. And, and while we're saying that, and yes, you're absolutely right, the final [LACC] reports were published in JCO recently. And I'm very grateful to the JCO editorial team that they accepted the paper, and they communicated the results because this is obviously very important. At the same time, I would like to say that there are now three or four RCTs that challenge the LACC data. These RCTs are ongoing, and a lot of people will be looking forward to having these results available. Dr. Ebony Hoskins: Very good. In early-stage cervical cancer, the SHAPE trial looked at simple versus radical hysterectomy in low-risk cervical cancer patients. And as well all know, simple hysterectomy was not inferior to radical hysterectomy with respect to the pelvic recurrence rate and any complications related to surgery such as urinary incontinence and retention. My question for you is have you changed your practice in early-stage cervical cancer, say a patient with stage 1B1 adenocarcinoma with a positive margin on conization, would you still offer this patient a radical hysterectomy or would you consider a simple hysterectomy? Dr. Andreas Obermair:  I think this is a very important topic, right? Because I think the challenge of SHAPE is to understand the inclusion criteria. That's the main challenge. And most people simplify it to 2 cm, which is one of the inclusion criteria but there are two others and that includes the depth of invasion. Dr. Marie Plante has been very clear. Marie Plante is the first author of the SHAPE trial that's been published in the New England Journal of Medicine only recently and Marie has been very clear upfront that we need to consider all three inclusion criteria and only then the inclusion criteria of SHAPE apply. So at the end of the day, I think what the SHAPE trial is telling us that small tumors that would strictly fulfill the criteria of a 1B or 1B1 cancer of the cervix can be considered for a standard type 1 or PIVA type 1 or whatever classification we're trying to use will be eligible. And that makes a lot of sense. I personally not only look at the size, I also look at the location of the tumor. I would be very keen that I avoid going through tumor tissue because for example, if you have a tumor that is, you know, located very much in one corner of the cervix and then you do a standard hysterectomy and then you have a positive tumor margin that would be obviously, most people would agree it would be an unwanted outcome. So I'd be very keen checking the location, the size of the tumor, the depths of invasion and maybe then if the tumor for example is on one side of the cervix you can do a standard approach on the contralateral side but maybe do a little bit more of a margin, a parametrial margin on the other side. Or if a tumor is maybe on the posterior cervical lip, then you don't need to worry so much about the anterior cervical margin, maybe take the rectum down and maybe try to get a little bit of a vaginal margin and the margin on the uterus saccals. Just really to make sure that you do have margins because typically if we get it right, survival outcomes of clinical stage 1 early cervix cancer 1B1 1B 2 are actually really good. It is a very important thing that we get the treatment right. In my practice, I use a software to record my treatment outcomes and my margins. And I would encourage all colleagues to be cognizant and to be responsible and accountable to introduce accountable clinical practice, to check on the margins and check on the number on the percentage of patients who require postoperative radiation treatment or chemo radiation. Dr. Ebony Hoskins: Very good. I have so many questions for you. I don't know the statistics in Australia, but here, there's increased rising of endometrial cancer and certainly we're seeing it in younger women. And fertility always comes up in terms of kind of what to do. And I look at the guidelines and, see if I can help some of the women if they have early-stage endometrial cancer. Your thoughts on what your practice is on use of someone who may meet criteria, if you will. The criteria I use is grade 1 endometrioid adenocarcinoma. No myometria invasion. I try to get MRI'd and make sure that there's no disease outside the endometrium. And then if they make criteria, I typically would do an IUD. Can you tell me what your practice is and where you've had success? Dr. Andreas Obermair: So, we initiated the feMMe clinical trial that was published in 2021 and it was presented in a Plenary at one of the SGO meetings. I think it was in 2021, and we've shown complete pathological response rates after levonorgestrel intrauterine device treatment. And so in brief, we enrolled patients with endometrial hyperplasia with atypia, but also patients with grade 1 endometrial adenocarcinoma. Patients with endometrial hyperplasia with atypia had, in our series, had an 85 % chance of developing a complete pathological response. And that was defined as the complete absence of any atypia or cancer. So endometrial hyperplasia with atypia responded in about 85%. In endometrial cancer, it was about half, it was about 45, 50%. In my clinical practice, like as you, I see patients, you know, five days a week. So I'm looking after many patients who are now five years down from conservative treatment of endometrial cancer. There are a lot of young women who want to get pregnant, and we had babies, and we celebrate the babies obviously because as gynecologist obstetricians it couldn't get better than that, right, if our cancer patients have babies afterwards. But we're also treating women who are really unfit for surgery and who are frail and where a laparoscopic hysterectomy would be unsafe. So this phase is concluded, and I think that was very successful. At least we're looking to validate our data. So we're having collaborations, we're having collaborations in the United States and outside the United States to validate these data. And the next phase is obviously to identify predictive factors, to identify predictors of response. Because as you can imagine, there is no point treating patients with a levonorgestrel intrauterine joint device where we know in advance that she's not going to respond. So this is a very, very fascinating story and we got our first set of data already, but now we just really need to validate this data. And then once the validation is done, my unit is keen to do a prospective validation trial. And that also needs to involve international collaborators. Dr. Ebony Hoskins: Very good. Moving on to ovarian cancer, we see patients with ovarian cancer with, say, at least stage 3C or higher who started neoadjuvant chemotherapy. Now, some of these patients are hearing different things from their medical oncologist versus their gynecologic oncologist regarding the number of cycles of neoadjuvant chemotherapy after getting diagnosed with ovarian cancer. I know that this can be confusing for our patients coming from a medical oncologist versus a gynecologic oncologist. What do you say to a patient who is asking about the ideal number of chemotherapy cycles prior to surgery? Dr. Andreas Obermair: So this is obviously a very, very important topic to talk about. We won't be able to provide a simple off the shelf answer for that, but I think data are emerging.  The ASCO guidelines should also be worthwhile considering because there are actually new ASCO Guidelines [on neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer] that just came out a few weeks ago and they would suggest that we should be aiming for R0 in surgery. If we can maybe take that as the pivot point and then go back and say, okay, so what do need to do to get the patient to zero?  I'm not an ovarian cancer researcher; I'm obviously a practicing gynecologic oncologist. I think about things a lot and things like that. In my practice, I would want a patient to develop a response after neoadjuvant chemotherapy. So, if a patient doesn't have a response after two or three cycles, then I don't see the point for me to offer her an operation. In my circle with the medical oncologists that I work with, I have a very, very good understanding. So, they send the patient to me, I take them to the theater. I take a good chunk of tissue from the peritoneum. We have a histopathologic diagnosis, we have a genomic diagnosis, they go home the same day. So obviously there is no hospital stay involved with that. They can start the chemotherapy after a few days. There is no hold up because the chances of surgical complication in a setting like this is very, very low. So I use laparoscopy to determine whether the patient responds or not. And for many of my patients, it seems to work. It's obviously a bit of an effort and it takes operating time. But I think I'm increasing my chances to make the right decision. So, coming back to your question about whether we should give three or six cycles, I think the current recommendations are three cycles pending the patient's response to neoadjuvant chemotherapy because my aim is to get a patient to R0 or at least minimal residual disease. Surgery is really, in this case, I think surgery is the adjunct to systemic treatment. Dr. Ebony Hoskins: Definitely. I think you make a great point, and I think the guideline just came out, like you mentioned, regarding neoadjuvant. And I think the biggest thing that we need to come across is the involvement of a gynecologic oncologist in patients with ovarian cancer. And we know that that survival increases with that involvement. And I think the involvement is the surgery, right? So, maybe we've gotten away from the primary tumor debulking and now using more neoadjuvant, but surgery is still needed. And so, I definitely want to have a take home that GYN oncology is involved in the care of these patients upfront. Dr. Andreas Obermair: I totally support that. This is a very important statement. So when I'm saying surgery is the adjunct to medical treatment, I don't mean that surgery is not important. Surgery is very important. And the timing is important. And that means that the surgeons and the med oncs need to be pulling on the same string. The med oncs just want to get the cytotoxic into the patients, but that's not the point, right? We want to get the cytotoxic into the patients at the right time because if we are working under this precision surgery, precision treatment mantra, it's not only important what we do, but also doing it at the right time. And ideally, I I would like to give surgery after three cycles of neoadjuvant chemotherapy, if that makes sense. But sometimes for me as a surgeon, I talk to my med onc colleagues and I say, “Look, she doesn't have a good enough response to her treatment and I want her to receive six cycles and then we re-evaluate or change medical treatment,” because that's an alternative that we can swap out drugs and treat upfront with a different drug and then sometimes they do respond. Dr. Ebony Hoskins:  I have maybe one more topic. In the area I'm in, in the Washington D.C. area, we see lots of endometrial cancer and they're not grade 1, right? They're high-risk endometrial cancer and advanced. So a number of patients with stage 3 disease, some just kind of based off staging and then some who come in with disease based off of the CT scan, sometimes omental caking, ascites. And the real question is we have extrapolated the use of neoadjuvant chemotherapy to endometrial cancer. It's similar, but not the same. So my question is in an advanced endometrial cancer, do you think there's still a role, when I say advanced, I mean, maybe stage 4, a role for surgery? Dr. Andreas Obermair: Most definitely. But the question is when do you want to give this surgery? Similar to ovarian cancer, in my experience, I want to get to R0. What am I trying to achieve here? So, I reckon we should do a trial on this. And I reckon we have, as you say, the number of patients in this setting is increasing, we could do a trial. I think if we collaborate, we would have enough patients to do a proper trial. Obviously, we would start maybe with a feasibility trial and things like that. But I reckon a trial would be needed in this setting because I find that the incidence that you described, that other people would come across, they're becoming more and more common. I totally agree with you, and we have very little data on that. Dr. Ebony Hoskins: Very little and we're doing what we can. Dr. Obermair, thank you for sharing your fantastic insights with us today on the ASCO Daily News Podcast and for all the work you do to advance care for patients with gynecologic cancer. Dr. Andreas Obermair: Thank you, Dr. Hoskins, for hosting this and it's been an absolute pleasure speaking with you today. Dr. Ebony Hoskins: Definitely a pleasure and thank you to our listeners for your time today. Again, Dr. Obermair's article is titled, “Controversies in the Surgical Management of Gynecologic Cancer: Balancing the Decision to Operate or Hesitate,” and was published in the 2024 ASCO Educational Book. And you'll find a link to the article in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Ebony Hoskins @drebonyhoskins Dr. Andreas Obermair @andreasobermair Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Ebony Hoskins: No relationships to disclose. Dr. Andreas Obermair: Leadership: SurgicalPerformance Pty Ltd. Stock and Ownership Interests: SurgicalPerformance Pty Ltd. Honoraria: Baxter Healthcare Consulting or Advisory Role: Stryker/Novadaq Patents, Royalties, and Other Intellectual Property: Shares in SurgicalPerformance Pty Ltd. Travel, Accommodation, Expenses: Stryker    

This episode discusses four MMWR reports. First, 2024-2025 COVID-19 vaccination provides additional protection against COVID-19-associated emergency department/urgent care encounters and hospitalizations. Second, this season's flu vaccines protect against flu-related medical visits and hospitalizations. Third, a new CDC report finds that 13% of children who have died from seasonal flu this season had influenza-associated encephalopathy or encephalitis, a potentially severe neurologic complication. Last, as HPV vaccination has increased, a steep decline in cervical precancers has occurred.

A study by the University of Otago shows the HPV vaccine has reduced cervical cancer by over 60 percent, while also lowering the risk of pre-cancerous changes. University of Otago Department of Obstetrics and Gynaecology professor Peter Sykes spoke to Corin Dann.

Eithne Dodd reports on efforts to improve the uptake of the HPV vaccine.

In this eye-opening episode of Menopause Mastery, our host sits down with Dr. Doni Wilson—a renowned naturopathic doctor, midwife, clinical nutritionist, and best-selling author—to uncover the hidden risks of HPV during menopause and how to take control of your health. Dr. Doni shares must-know insights on HPV, cervical cancer risks, and the limitations of conventional medicine's "watch and wait" approach—plus practical strategies to clear the virus naturally and strengthen your immune system. Learn why stress, hormone shifts, and microbiome imbalances make midlife women more vulnerable, and how to boost your body's defenses with nutrition, functional medicine, and holistic therapies. If you're in your 40s, 50s, or beyond, this conversation is a must-listen. Whether you've been diagnosed with HPV or want to stay proactive about your health, Dr. Doni provides the knowledge and tools to help you protect yourself, take action, and reduce cervical cancer risks. Chapters: 00:00 - Welcome to Menopause Mastery 00:09 - Introducing Dr. Doni Wilson 00:24 - Why HPV Still Matters in Midlife 01:09 - The Link Between HPV and Cervical Cancer 02:17 - High-Risk HPV: What You Need to Know 06:04 - How HPV is Diagnosed and Treated 10:19 - The Cycle of Procedures & Why It Persists 16:06 - Can You Really Clear HPV? 20:25 - Stress, Immunity & HPV Risk Factors 32:00 - How to Take Action & Protect Yourself Links: Menrva Telemedicine: https://gethormonesnow.com/ FREE Hormone Quiz: https://bit.ly/3wNJOec Living Well Dallas: https://www.livingwelldallas.com/ Hormone Reset: https://hormonereset.net/ Betty Murray Website: https://www.bettymurray.com/ Facebook: https://www.facebook.com/BettyAMurrayCN/ Instagram: https://www.instagram.com/bettymurray_phd/ Produced by Evolved Podcasting: www.evolvedpodcasting.com Connect with Dr. Betty Murray: Website: https://www.bettymurray.com/ Facebook: https://www.facebook.com/BettyAMurrayCN/ Instagram: https://www.instagram.com/bettymurray_phd/ Thank you for listening to Menopause Mastery. Empowering your health journey, one episode at a time.

Dr. Eckert is a board-certified obstetrician and gynecologist and an internationally recognized expert in immunizations and cervical cancer prevention, she joins Megan Lynch. Her new book "Enough - Because we can stop cervical cancer" is available now.

Today, a story that starts small and private, with one woman alone in her bathroom, as she makes a quiet, startling discovery about her own body. But that small, private moment grows and grows, and pretty soon it becomes something so big that it has impacted the life of every person reading this right now… and all that without the woman ever even knowing the impact she had. We originally aired this story back in 2010, but we thought we'd bring it back today, as questions about bodily autonomy circle with renewed force.EPISODE CREDITS: Reported by - Rebecca SklootSignup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Gordon and Betty Moore Foundation, Science Sandbox, a Simons Foundation Initiative, and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

Surviving stage IV cancer was a journey of faith, transformation, and inner strength. Embracing faith gave Amber hope when the path seemed dark. She changed my diet, nourishing my body with what it needed to heal. Meditation became her sanctuary, helping her find peace amidst the storm. Acceptance was her turning point— She accepted her diagnosis, her journey, and the changes she needed to make. Through this, Amber discovered resilience she had never known she had. Each step, each moment of faith, and each mindful choice led her to a place of healing and renewal, stronger and more grateful than ever. For her family, this journey has been marked by growth, challenges, and an unwavering commitment to family and faith. To connect with Amber directly, email her at amberalessandri@gmail.com or on Instagram Resources Mentioned in this Episode: - Immermans Angels visit https://imermanangels.org/ - Book: Crazy, Sexy Cancer by Kris Carr   - Documentaries:  Watch Heal on Prime Video   Watch The C Word on Prime Video  ----more---- To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube ----more---- Thank you to our friends from The Healing Oasis for sponsoring this episode of the podcast.  The Healing Oasis is a first of its kind in beautiful British Columbia, Canada where we encourage the body to heal from cancer using alternative therapies & cancer fighting meals at a wellness retreat center in nature. Our top naturopathic cancer doctor will prescribe a protocol tailored specifically for you. There's no place quite like it. Start your healing journey today! Learn More about The Healing Oasis by visiting these links: Website   Testimonials Video Overview

- Overview of Cervical Cancer, Including Diagnosis & Staging - Combination Treatments - How Precision Medicine & Testing Inform Your Treatment Decisions - New & Emerging Treatment Approaches - The Role of the Pathologist - Biomarkers, Diagnostic Technologies, Sequencing of Treatments - Updates on Clinical Trials - How Research Increases Treatment Options - Nutrition & Hydration Tips & Suggestions - Questions for Our Panel of Experts

In the first Q&A episode of the Gladden Longevity Podcast in 2025, Dr. Jeffrey Gladden and Steve Reiter discuss various aspects of health optimization, including new developments in dementia treatment going on at Gladden Longevity, the importance of thyroid health, challenges in cancer screening, and a holistic and mind-shifting approach to getting in the best shape of your life in 2025. The conversation emphasizes actionable insights for listeners to enhance their youthfulness, lifespan and overall well-being.   FOR THE AUDIENCE ·      Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways   ·      New trials are exploring effective treatments for dementia. ·      Thyroid health is crucial for cognitive function and overall health. ·      Cancer screening methods are often inadequate and need improvement. ·      It's impossible to get truly in shape in a gym. ·      A holistic approach to fitness involves training the nervous system, not just muscles. ·      Daily physical activity is essential for maintaining health and fitness. ·      Understanding individual health markers can lead to better health outcomes. ·      Nutrition, including iodine and minerals, plays a significant role in health. ·      Engaging in diverse physical activities can enhance overall fitness.    Chapters   00:00 Introduction to Age Hacking and Longevity 02:00 New Developments in Dementia Treatment 08:06 Thyroid Health and Cognitive Function 14:51 Cancer Screening and Prevention Challenges 25:50 Getting in Shape for 2025: A Holistic Approach 41:24 Goodbye   Articles, News and Supplements mentioned  Cervical Cancer CERVICAL SCREENING KNOWLEDGE GAP ‘COSTING LIVES' https://www.bbc.com/news/articles/cvg44pr28ywo.amp?xtor=AL-%5B72%5D-%5Bpartner%5D-%5Bsmart.news%5D-%5Bheadline%5D-%5Bnews%5D-%5Bbizdev%5D-%5Bisapi%5D   Thyroid DOCTORS WORRIED THAT IODINE DEFICIENCY – A PROBLEM FROM THE PAST – IS COMING BACK https://nypost.com/2025/01/21/health/doctors-warn-that-iodine-deficiency-a-dietary-problem-from-the-past-is-coming-back/?utm_source=smartnews&utm_campaign=nypost&utm_medium=referral   Supplements IODINE https://gladdenlongevityshop.com/products/upgraded-iodine-thyroid-support?_pos=1&_psq=iodine&_ss=e&_v=1.0   ANTI-INFLAMMATORY SHROOM FORMULA https://gladdenlongevityshop.com/products/anti-inflammatory-adaptogenic-mushrooms?_pos=2&_psq=shroom&_ss=e&_v=1.0   SHROOM IMMUNE https://gladdenlongevityshop.com/products/shroom-immune-60ct?_pos=1&_psq=shroom&_ss=e&_v=1.0   TRACE MINERALS https://gladdenlongevityshop.com/products/trace-minerals-60caps?_pos=1&_psq=mineral&_ss=e&_v=1.0   Send your Qs for future episodes!  Email: podcast@gladdenlongevity.com    Reach out to us at:  Website: https://gladdenlongevity.com/   Facebook: https://www.facebook.com/Gladdenlongevity/  Instagram: https://www.instagram.com/gladdenlongevity/?hl=en   LinkedIn: https://www.linkedin.com/company/gladdenlongevity  YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw  

Send us a textListen to this replay of "Cervical Cancer Awareness" from Season 2 with guest Dr. Sharon Sutherland from the Cleveland Clinic. Speaking of Women's Health Podcast host Holly Thacker, MD focuses her questions on raising awareness about cervical cancer and the importance of regular screenings to prevent it.January is Cervical Cancer Awareness month, so there's no better time to hear about how you can prevent cervical cancer with regular screenings.Fit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts SpotifySupport the show

A couple receives the biggest surprise blessing after a cervical cancer diagnosis. AND It was both guardian angels and human heroes who saved a 75-year-old woman when they rescued her from her overturned car in late 2024. To see videos and photos referenced in this episode, visit GodUpdates! https://www.godtube.com/blog/blessing-cervical-cancer-diagnosis.html https://www.godtube.com/blog/family-rescued-woman-from-car.html Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

In honor of Cervical Health Awareness Month, the National Cervical Cancer Coalition presents the Cervical Cancer Survivor Series. Across eight episodes, we share stories from cervical cancer survivors across the country, touching on topics including diagnosis, treatment, and survivorship, as well as advice for others whose lives are impacted by this preventable disease. We also talked to providers in the field to answer questions about screening prevention and treatment. In this final episode, we hear from all of our survivors from this series—Jen English, Shaundra Hall, Aisha McClellan, Selena Rushton, and Cheryla Thompson. We talked to them about a range of topics, including advice they've received and would offer others after a diagnosis, how family and friends can best offer support to loved ones dealing with cancer, what they would say to anyone considering the HPV vaccine, and why they decided to become involved in advocacy.

In honor of Cervical Health Awareness Month, the National Cervical Cancer Coalition presents the Cervical Cancer Survivor Series. Across eight episodes, we share stories from cervical cancer survivors across the country, touching on topics including diagnosis, treatment, and survivorship, as well as advice for others whose lives are impacted by this preventable disease. We also talked to providers in the field to answer questions about screening prevention and treatment. In this episode we speak to gynecological oncologist, Brad Monk. Dr. Monk leads clinical trials and has authored or co-authored over 300 peer-reviewed publications on cervical cancer, ovarian cancer, and other gynecologic cancers and also sees patients. We talked to Dr. Monk about finding a cancer expert and possible treatment options.

Lawmakers and education officials are looking into ways to reduce the number of children in the state's underperforming school districts.Then, Mississippi has a high rate of cervical cancer. Physicians say getting vaccinated for HPV is one of the most effective ways to prevent the disease.Plus, energy providers are sharing tips on how to keep your home warm without breaking the bank. Hosted on Acast. See acast.com/privacy for more information.

In this episode during the month of January, we discuss this Transformational moment in history that we are all experiencing. It is not always easy and yet every challenge of our lives is an opportunity to grow and to determine the way forward towards a better, healthier and more Joyful, Happy and Meaningful life. A life grounded in Service, to creating greater health for many and reducing dis-ease. While my focus is in helping woman this extends to men as well Watch here: https://youtu.be/MD-HLsV2GW4

Daniel Petereit, M.D., FASTRO, Monument Health Radiation Oncologist, and Keely Ulmer, M.D., University of Iowa Gynecologic Oncologist, join host Leslie Cline to discuss the groundbreaking work in cervical cancer screening. In this episode, Drs. Petereit and Ulmer discuss the barriers faced when encouraging healthy people to get early prevention testing as well as accessing care, including the discomfort and fears associated with traditional screening methods. They explore the promising shift toward self-collection HPV testing, which provides a less invasive, more accessible option for people to screen for cervical cancer from the comfort of their own homes. They also dive into their current research, which aims to engage and educate rural and Native American communities about the benefits of this new screening method. The duo share insights on how this initiative could greatly reduce mortality rates of cervical cancer for all communities, while empowering people to take more control over their health care. Dr. Ulmer also discusses her efforts to mentor the next generation of Native American health care professionals, emphasizing the importance of representation in medicine. Hosted on Acast. See acast.com/privacy for more information.

The SpaceX rocket carries lunar landers from companies based in Texas and Japan. They could arrive at the moon in the coming months. HPV can cause a variety of cancers, including cervical. New mortality data for women under 25 point to the success of the HPV vaccine.Rocket Launches With Lunar Landers From 2 Private CompaniesOn Wednesday, a SpaceX rocket launched carrying payloads from two separate private companies hoping to achieve lunar landings. The pair of landers—one from Japanese company ispace, and one from Texas-based Firefly Aerospace—will take months to reach the moon. Firefly's lander is scheduled to arrive first, in March, with ispace's lander planned for a touchdown in late May or early June.Another SpaceX launch on Thursday, a test flight of the company's Starship system, had mixed results. The booster returned to earth and was successfully “caught,” but the spacecraft exploded over the Caribbean shortly after launch. That explosion is under investigation.Jason Dinh, climate editor at Atmos in Washington, D.C., joins Ira to talk about the Wednesday launch and plans for private lunar exploration. They also discuss other stories from the week in science, including the ban of Red Dye #3 an AI approach to snake antivenom, and a study predicting a rise in US dementia cases by 2060.As Cervical Cancer Deaths Plummet, Experts Credit HPV VaccineIn 2006, a vaccine for the human papillomavirus (HPV) became widely available to adolescents. HPV is the most common sexually transmitted infection, and it can cause cancers of the mouth, throat, and sexual organs. It's also the cause of nearly every case of cervical cancer.Now, almost 20 years after the HPV vaccine was introduced, a study published in JAMA noted a 62% drop in deaths due to cervical cancer in women under 25 in the US: from 50 or 60 deaths per year to 13. This follows earlier research that noted a decrease in cervical precancer and cancer since the introduction of the vaccine.With HPV vaccine uptake at about 60% for adolescents aged 13-15, a higher uptake could virtually eliminate cervical cancer, experts say. However, childhood vaccination rates have dwindled since the start of the COVID-19 pandemic, sparking concerns about the spread of preventable disease.Joining Flora Lichtman to talk about this latest study is lead author Dr. Ashish Deshmukh, professor of public health sciences and co-leader of the Cancer Prevention and Control Program at the Medical University of South Carolina in Charleston, South Carolina.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dr. Linda Eckert, author of "Enough: Because We Can Stop Cervical Cancer," is a recognized expert in immunizations and cervical cancer prevention having worked as a consultant with the World Health Organization on global cancer prevention for the last fifteen years, facilitating policy development for the HPV vaccine and cervical cancer screening.

Episode 182: HPV VaxFuture Dr. Zuaiter and Dr. Arreaza briefly discuss HPV infection but pocus on the prevention of the infection with the vaccine. Dr. Arreaza mentions that HPV vaccine is also recommended by ASCCP to medical professionals. Written by Amanda Zuaiter, MS4, Ross University School of Medicine. Edits and comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Human Papilloma Virus (HPV).According to the World Health Organization, cervical cancer is the 4th most common cancer affecting women globally. Annually, there are over 600,00 new cases and more than 300,000 deaths. The leading cause of cervical cancer is HPV. HPV, or human papillomavirus, is a prevalent virus that is spread through close skin-to-skin contact, mainly by sexual intercourse. It is the most common sexually transmitted disease in the United States. The term STI and STD are used indistinctively, but some people make a difference, such as Dr. Cornelius Reitmeijer. STI refers to sexually transmitted infection, which can be asymptomatic, and STD stands for sexually transmitted disease, which are the signs and symptoms caused by the multiplication of the infectious agent and disruption of bodily functions. STI is the preferred term, as recommended by experts during the last few years.  Low risk vs High risk HPV.There are over 200 strains of HPV which fall into two categories: low risk and high risk. The low-risk types, HPV 6 and 11, cause warts around the genitals, anus, mouth or throat. The high-risk types, HPV 16 and 18, are linked to cervical, vaginal, anal, and other cancers. Persistent infection with high-risk HPV types is the primary cause of cervical cancer, accounting for 70% of cervical cancer cases. While often asymptomatic, persistent HPV infections can develop into papular lesions which can cause bleeding and pain or cause sore throat and hoarseness if warts develop in the throat.Not all warts will turn into cancer, but the risk of a wart turning into cancer is higher than normal skin or mucosa that has not been infected by HPV.Even though cervical cancer is the most well-known condition linked to HPV, it's important to note that HPV isn't just a women's health issue. It can also cause cancers in men, such as throat, penile and anal cancers. Men, however, are not screened for HPV if they have no signs or symptoms of infection.HPV Prevention: General measures that can be taken are maintaining a healthy immune system by exercising regularly and a balanced diet and quitting smoking.Male circumcision has been shown to reduce the risk of penile cancer in men and their sexual partners may have a lower risk of cervical cancer. Screening: Women should undergo regular pap smears with HPV screening. Pap smear screening begins at the age of 21 and is recommended every 3 years. From ages 30-65, co-testing should be done every 5 years, according to the guidelines by the American College of Obstetrics and Gynecology. Also, HPV test self-collection is now available in the US since May 2024, and it is useful especially in rural areas.The most effective ways to prevent the transmission of HPV is to practice safe sex, using condoms, and getting vaccinated. HPV vaccine. For medical providers: It was announced only to ASCP (American Society for Colposcopy and Cervical Pathology) members in the middle of the pandemic. On February 19, 2020, ASCCP recommended HPV vaccination for clinicians routinely exposed to the virus.This recommendation encompasses the complete health care team, including but not limited to, physicians, nurse practitioners, nurses, residents, and fellows, as well as office and operating room staff in the fields of obstetrics and gynecology, family practice, gynecologic oncology, and dermatology. Let's remember that in 2018, the FDA a supplemental application for Gardasil 9 to include persons aged 27 to 45 years old. The ASCCP letter states “While there is limited data on occupational HPV exposure, ASCCP, as well as other medical societies, recommend that members actively protect themselves against the risks” among medical providers. For patients: The vaccine is given to prevent the types of HPV that are most likely to cause cancer and other health problems. It works by training the immune system to recognize and fight HPV before an infection can take hold. Gardasil-9® is the brand name that is offered in the US. The 9 means it targets 9 strains of the virus (6, 11, 16, 18, 31, 33, 45, 52, and 58). It's important to note that the vaccine is preventative, and it is not considered a treatment. This means it's most effective when given BEFORE any exposure to HPV, ideally during adolescence. The HPV vaccine is recommended for boys and girls ages 11-12 but can be started as early as the age of 9. We need to be prepared to manage vaccine hesitancy because some parents may be concerned when you explain the vaccine to them. A study done in Scotland found that there were NO cases of invasive cervical cancer in adults who received any doses of the HPV vaccine at 12 to 13 years of age. To get to that conclusion, they reviewed the cancer data of 447,845 women who were born between 1988 and 1996. The data demonstrated that the HPV vaccine prevents invasive cervical cancer, especially when given between 12 to 13 years of age. When the vaccine is given later in life, it tends to be less effective. AmandaHow is HPV vaccine given?The vaccine schedule is as follows: -For ages 9-14, two shots are given with the second dose 6-12 months after the first. -For those ages 15-26, three shots are given. After the first shot, the second is given after 1-2 months, and the third shot 6 months after the first. This is the same schedule for immunocompromised people regardless of their age. -People over the age of 26 can still receive the vaccine, as the FDA has approved the vaccine for individuals up to the age of 45. With that being said, those over the age of 26 may not fully benefit from the vaccine due to the fact they may have already been exposed to HPV. Still, vaccination can provide protection against other strains of the virus.Other HPV Vaccine considerations:Is HPV vaccine effective?-Studies have shown that the HPV vaccine is nearly 100% effective at preventing cervical pre-cancers caused by HPV 16 and 18.Are boosters needed?-The vaccine provides protection for at least 10 years and boosters are not required. The vaccine is recommended for boys too, as they are also at risk for HPV causing cancers, and administration of the vaccine helps to reduce the spread of the virus. It is safe to administer the HPV vaccine with all other age-appropriate vaccinations. What if my patient misses a dose?-If a dose is missed, it can be resumed at any time without restarting the series. There are no known severe side effects or reactions to the vaccine. The vaccine can be given even if the person has already been exposed to HPV as it can protect against the other types of HPV.Conclusion: HPV is a common cause of cervical cancer, and the benefits of the HPV vaccine are profound. Countries with high vaccination rates have already seen significant drops in HPV infections, genital warts, and cervical pre-cancers. Vaccination protects individuals and helps achieve herd immunity, benefiting entire communities.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Sabour, Jennifer, “The Difference Between STD and STI,” Verywell Health, August 22, 2024, https://www.verywellhealth.com/std-vs-sti-5214421. ASCCP Letter, February 19, 2020, https://www.asccp.org/hpv-vaccinationBarry HC. Scottish Screening: No Cases of Invasive Cervical Cancer in Women Who Received At least One Dose of Bivalent HPV Vaccine at 12 or 13 Years of Age. Am Fam Physician. 2024 Aug;110(2):201-202. PMID: 39172683. https://pubmed.ncbi.nlm.nih.gov/39172683/World Health Organization. “Cervical Cancer,” March 5, 2024, www.who.int/news-room/fact-sheets/detail/cervical-cancerACOG, “Cervical Cancer Screening FAQ,” www.acog.org/womens-health/faqs/cervical-cancer-screening. Accessed January 9, 2025.ACOG, “HPV Vaccination FAQ,” www.acog.org/womens-health/faqs/hpv-vaccination. Accessed January 9, 2025.Cox, J. Thomas and Joel M Palefsky, UpToDate, www.uptodate.com/contents/human-papillomavirus-vaccination, accessed January 9, 2025.National Cancer Institute. “HPV and Cancer.” National Cancer Institute, 18 Oct. 2023, www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer .Theme song, Works All the Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Join our Math Clinic Event on January 20-22 to sharpen your skills in dosage calculations, conversions, and everything you need for nursing success! Don't wait—sign up now at ReMarNurse.com/Clinic   In this informative video, Prof. Regina Callion, MSN, RN—the #1 instructor on the planet breaks down everything nursing students need to know about cervical cancer, a condition that impacts thousands of women worldwide.   You'll learn what cervical cancer is, the key risk factors (like HPV infection, smoking, and a weakened immune system), and the common signs and symptoms to look for, such as unusual bleeding and pelvic pain. Prof. Callion also emphasizes the importance of screening tests like Pap smears and HPV tests for early detection, as well as explains the various treatment options, including surgery, radiation, and chemotherapy.   Download the ReMar V2 App: ►For iOS: https://apps.apple.com/us/app/remar-v... ►For Android: https://play.google.com/store/apps/de... ► Find JOBS: http://ReMarNurse.com/jobs ► NCLEX for Africa - http://ReMarNurse.com/KENYA ► Get NCLEX V2: http://www.ReMarNurse.com ► Join the 30-day Challenge - http://ReMarNurse.com/30DAYS

Have you ever wondered how you can lower your risk of cervical cancer right now? This episode isn't just for you—it's for every woman you care about. Dr. Stephanie Hack, MD, MPH, our trusted OB/GYN and women's health expert, reveals everything you need to know about preventing cervical cancer at every stage of life. From the power of the HPV vaccine to the life-saving importance of screenings in your 20s, 30s, 60s, and beyond, she breaks it all down in a way that's practical, empowering, and easy to follow. We'll also uncover the shocking truth about racial disparities in cervical cancer and how we can work together to create change.As you build your self-care practice for 2025, routine screenings are an essential act of love—not just for yourself but for the women who look up to you, lean on you, and walk beside you. Listen in, then share this life-changing conversation with your sisters, friends, mothers, and daughters—because knowledge saves lives.

The health of our military service members and our Veterans is always a top line issue. Many suffer from illness and injury as a result of their service; and most are believed to be at higher risk for chronic sickness. Some of which is fortunately preventable. Cancer is a top concern for much of the military community. To dig into the increased risk cancer poses to our Veterans, Fran Racioppi sat down with Team Maureen; an organization focused on bringing attention and prevention of HPV and HPV-related cancers to our Veterans. Daniel Linskey, Kelly Welch and Dr. Emily Penick lead Team Maureen and founded the organization after the loss of their family and friend Maureen Russo. Worldwide, a woman dies of cervical cancer every two minutes. It is the second-most frequent cancer in the world. The military community is twice as likely to develop HPV, yet immunization rates among our servicemembers are 50% of the civilian community. 90% of HPV-related cancers are preventable through immunization.We broke down the facts of HPV, why it's rising exponentially in our military, how it's affecting both our women and men service-members, and what every single person, military and civilian, can do to prevent one of the deadliest, and preventable, cancers in society today.Check out our conversation over-looking Plymouth Harbor and with Cardinals in the air. Follow us on social media, read the full episode on our website, then head over to our YouTube channel or your favorite podcast platform to catch this conversation and our follow-up with Danny as he shares how he led the Boston Police Department during the 2013 Boston Marathon bombing. HIGHLIGHTS0:00 Introduction1:50 Welcome to the South Shore4:44 What is Cervical Cancer?8:09 How do you get Cervical Cancer?9:49 What is the effect on men?11:38 Screening for HPV12:55 Oral Health importance14:23 Low vaccination rates17:40 Why are military at risk?19:58 Vaccination process24:57 Who was Maureen?29:17 How are you educating people?33:20 How do you get involved?QUOTES“Making sure that people know about the importance of prevention of HPV and early detection for cervical cancer is our mission.”“Nobody should die of cervical cancer. It's completely preventable.” “Why not be at the forefront of HPV prevention?” “This is something that can help your kids not get cancer.” “Active duty military and Veterans are 2x as likely as civilians to develop cancers associated with HPV.” “We should be able to get to that point where no one loses a loved one to cervical cancer.”“You think you're a badass. Cancer doesn't care if you're a badass.” The Jedburgh Podcast and the Jedburgh Media Channel are an official program of Green Beret Foundation, supporting US Army Special Forces of all generations.

In honor of Cervical Health Awareness Month, the National Cervical Cancer Coalition presents the Cervical Cancer Survivor Series. Across eight episodes, we share stories from cervical cancer survivors across the country, touching on topics including diagnosis, treatment, and survivorship, as well as advice for others whose lives are impacted by this preventable disease. We also talked to providers in the field to answer questions about screening prevention and treatment. In this episode, we speak to Aisha McClellan. Aisha went to a clinic with symptoms, and was sent home with antibiotics for an STI she didn't have. It took three visits before she was diagnosed with cervical cancer. Aisha had to be her own advocate for health care, which inspired her to become an advocate on TikTok, where she has over 25,000 followers. Follow Aisha on TikTok at https://www.tiktok.com/@aisha_the_advocate Learn more about cervical cancer prevention at the National Cervical Cancer Coalition website at www.nccc-online.org/

In honor of Cervical Health Awareness Month, the National Cervical Cancer Coalition presents the Cervical Cancer Survivor Series. Across eight episodes, we share stories from cervical cancer survivors across the country, touching on topics including diagnosis, treatment, and survivorship, as well as advice for others whose lives are impacted by this preventable disease. We also talked to providers in the field to answer questions about screening prevention and treatment. In this episode we speak to Shaundra Hall. Shaundra tells us that her very first Pap test came back abnormal, but she still didn't know anything about cervical cancer when she was diagnosed. She also talks about how this experience changed the course of her life, both personally and professionally. To learn more about clinical trials, visit https://clinicaltrials.gov. Learn more about Shaundra and her NCCC chapter at http://www.nccc-online.org/nccc-arizona-southwest-regional/ Learn more about cervical cancer prevention at the National Cervical Cancer Coalition website at www.nccc-online.org/

In honor of Cervical Health Awareness Month, the National Cervical Cancer Coalition presents the Cervical Cancer Survivor Series. Across eight episodes, we share stories from cervical cancer survivors across the country, touching on topics including diagnosis, treatment, and survivorship, as well as advice for others whose lives are impacted by this preventable disease. We also talked to providers in the field to answer questions about screening prevention and treatment. In this episode we speak to Jen English. Jen had a lot of experience in sexual health, and was comfortable talking about the topic, but she realized how much she didn't know about HPV and cervical health when she was diagnosed with early stage cervical cancer. Her experience inspired her to become an NCCC chapter leader. Learn more about Jen and her NCCC chapter at https://www.nccc-online.org/nccc-iowa-cedar-rapids-chapter/ Learn more about cervical cancer prevention at the National Cervical Cancer Coalition website at www.nccc-online.org/